“Success in the life sciences venture business is primarily driven by people - those you invest in and those you invest with.”  

Broad transaction experience and a wide network enable Scott to provide assistance to companies when raising capital, forming strategic partnerships and analyzing exit options.

Prior to joining Pappas Ventures in 2006, Scott was an investment manager and research analyst for Silverback Asset Management’s life science fund, where he focused on healthcare securities investing. Before joining Silverback, he spent three years at Chicago Growth Partners (formerly William Blair Capital Partners) as a Vice President focusing on healthcare venture capital investments. Previously, he spent three and a half years in investment banking at Lehman Brothers. There, he worked in the healthcare group in New York covering biotechnology, medical devices and drug delivery; the financial sponsors/leveraged finance group in London; and the media/telecom group in Hong Kong.

Scott currently serves as a director for Gentis, Milestone Pharmaceuticals and Rotation Medical; and as an observer for Envisia Therapeutics, IlluminOss Medical, Liquidia Technologies and Thrasos Therapeutics. He previously served as a board observer for LipoScience (NASDAQ: LPDX), and TESARO (NASDAQ: TSRO). Scott is also a member of the Investor Advisory Board of the Florida Institute for the Commercialization of Public Research, and a board member for the Council for Entrepreneurial Development (CED).


Duke University (BS in Biological Anthropology and Anatomy)
Duke University Fuqua School of Business (MBA)


Serves as a Director for:
  • Gentis, Inc.
  • Milestone Pharmaceuticals, Inc.
  • Rotation Medical, Inc.
Serves as an Observer for:
  • Envisia Therapeutics, Inc.
  • IlluminOss Medical, Inc.
  • Liquidia Technologies, Inc.
  • Thrasos Therapeutics, Inc.
  • Investor Advisory Board Member, Florida Institute for the Commercialization of Public Research
  • Board Member, Council for Entrepreneurial Development (CED)